Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

Jurriaan M.J.L. Brouwer, Marga Nijenhuis*, Bianca Soree, Henk Jan Guchelaar, Jesse J. Swen, Ron H.N. van Schaik, Jan van der Weide, Gerard A.P.J.M. Rongen, Anne Marie Buunk, Nienke J. de Boer-Veger, Elisa J.F. Houwink, Roos van Westrhenen, Bob Wilffert, Vera H.M. Deneer, Hans Mulder

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here, presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and antidepressants of the selective serotonin reuptake inhibitor type (SSRIs). Both genes’ genotypes are translated into predicted normal metabolizer (NM), intermediate metabolizer (IM), poor metabolizer (PM), or ultra-rapid metabolizer (UM). Evidence-based dose recommendations were obtained, based on a structured analysis of published literature. In CYP2C19 PM patients, escitalopram dose should not exceed 50% of the normal maximum dose. In CYP2C19 IM patients, this is 75% of the normal maximum dose. Escitalopram should be avoided in UM patients. In CYP2C19 PM patients, citalopram dose should not exceed 50% of the normal maximum dose. In CYP2C19 IM patients, this is 70% (65–75%) of the normal maximum dose. In contrast to escitalopram, no action is needed for CYP2C19 UM patients. In CYP2C19 PM patients, sertraline dose should not exceed 37.5% of the normal maximum dose. No action is needed for CYP2C19 IM and UM patients. In CYP2D6 UM patients, paroxetine should be avoided. No action is needed for CYP2D6 PM and IM patients. In addition, no action is needed for the other gene-drug combinations. Clinical effects (increase in adverse events or decrease in efficacy) were lacking for these other gene-drug combinations. DPWG classifies CYP2C19 genotyping before the start of escitalopram, citalopram, and sertraline, and CYP2D6 genotyping before the start of paroxetine as “potentially beneficial” for toxicity/effectivity predictions. This indicates that genotyping prior to treatment can be considered on an individual patient basis.

Original languageEnglish
Pages (from-to)1114–1120
JournalEuropean Journal of Human Genetics
Volume30
Early online date16 Nov 2021
DOIs
Publication statusPublished - 2022

Fingerprint

Dive into the research topics of 'Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs'. Together they form a unique fingerprint.

Cite this